Related Experiment Videos
Targeted toxins as anticancer agents
1Department of Molecular Immunology, Bristol-Myers Squibb, Pharmaceutical Research Institute, Seattle, Washington 98121.
Abstract:
Transformed cells, such as those found in breast cancer, often overexpress a variety of cell surface receptors and antigens. Antibodies or growth factors that specifically recognize these membrane-bound structures can be linked with protein toxins, resulting in cell-specific cytotoxic reagents. Many of these cytotoxic molecules have been produced and are referred to as oncotoxins, mitotoxins, or immunotoxins, depending on the components of the chimeric molecule. These bifunctional reagents are constructed as either chemical conjugates or fusion proteins between a ligand/antibody and a toxin. This report focuses on the use of cytotoxic proteins targeted to epidermal growth factor receptors, fibroblast growth factor receptors, erbB-2/HER-2, and tumor-associated carbohydrate antigens. Using immunotoxin therapy, total regression of established tumors in animal xenograft models have been demonstrated. These results suggest that immunotoxin molecules offer exciting opportunities for the treatment of human cancer.
Insights
Immunotoxins, which link antibodies to toxins, show promise for cancer treatment. These targeted therapies have demonstrated complete tumor regression in animal models, offering new hope for human cancer therapy.
Area of Science:
- Oncology
- Biotechnology
- Molecular Biology
Background:
- Transformed cancer cells frequently overexpress specific cell surface receptors and antigens.
- Targeting these membrane-bound structures is a key strategy in developing cell-specific therapies.
Purpose of the Study:
- To review the development and application of immunotoxins for cancer treatment.
- To highlight the potential of cytotoxic proteins targeting specific cancer cell receptors.
Main Methods:
- Construction of bifunctional reagents (immunotoxins) as chemical conjugates or fusion proteins.
- Linking antibodies or growth factors to protein toxins for targeted delivery.
- Focus on cytotoxic proteins targeting epidermal growth factor receptors, fibroblast growth factor receptors, erbB-2/HER-2, and tumor-associated carbohydrate antigens.
Main Results:
- Demonstrated total regression of established tumors in animal xenograft models using immunotoxin therapy.
- Successful targeting of specific cell surface receptors and antigens on cancer cells.
Conclusions:
- Immunotoxin molecules represent a promising therapeutic strategy for human cancer treatment.
- Targeted cytotoxic therapies offer exciting opportunities for effective cancer intervention.